 What started as a seemingly innocuous leadership transition at one of the countrys leading molecular diagnostic firms, NeoGenomics, Inc., has evolved into something much more chaotic. After the departure of former NeoGenomics, Inc. CEO and company veteran Douglas VanOort last year, things quickly turned toxic after the abrupt departure of his successor Mark Mallon. 